Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT00378105Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2006
- Primary completion
- Jul 2009
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by Dana-Farber Cancer Institute. Started Sep 2006; status: active, not recruiting.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00378105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378105.